Other publications discussed: user-friendly intuitive eCOA design, flexible data collection and monitoring methods, patient-centered protocol design, and comprehensive participant and site training
(ii) stimulation of adiponectin levels
Discussion While GLP-1 RAs are powerful anti-obesity medications (AOMs), they do raise some serious concerns most notably, up to 40% of the profound weight loss induced by these agents can be due to loss of lean mass 3,4,5 and prior studies have shown that a significant portion of this lean mass is muscle 33,34,35
The European Commission also approved the . - , which Novo Nordisk says demonstrated %* in its #clinical development programme
Once activated, several beneficial processes begin: Appetite signals to the brain increase: GLP-1 communicates with appetite centers in the brain, particularly areas involved in satiety regulation